Skyrizi and Rinvoq Redefine AbbVie's Manufacturing Priorities

AbbVie's Q1 2026 results confirm that the post-Humira transition is no longer a risk to be managed but a structural reality demanding sustained manufacturing and supply chain commitment. With immunology net revenues reaching $7.290 billion, up 14.3 percent on an operational basis, the volume obligations now resting on Skyrizi and Rinvoq production lines carry direct implications for capacity planning, process validation, and GMP compliance across AbbVie's biologics and small-molecule networks.

Skyrizi posted global net revenues of $4.483 billion, a 29.2 percent operational increase, while Rinvoq reached $2.119 billion, up 20.2 percent operationally. Against these figures, Humira net revenues declined 40.3 percent operationally to $688 million, underscoring how decisively biosimilar competition has redistributed demand. For QA directors and plant heads, the throughput requirements for two mechanistically distinct assets scaling simultaneously represent a non-trivial validation and batch release burden under 21 CFR Part 211 and ICH Q10 frameworks.

The oncology portfolio introduces a counterpoint that warrants attention from pipeline and capacity planners. Global oncology net revenues were $1.631 billion, a 3.0 percent operational decline. Venclexta contributed $770 million and Imbruvica $556 million, while Elahere recorded $198 million. The segment's contraction, even modest, raises questions about where capital investment and manufacturing slot allocation will be directed as AbbVie balances a high-growth immunology franchise against an oncology book that is not expanding at pace.

The neuroscience portfolio delivered $2.875 billion, up 24.3 percent operationally, with Botox Therapeutic at $1.009 billion and Vraylar at $905 million. Ubrelvy grew 41.2 percent operationally to $339 million. Total worldwide net revenues were $15.002 billion, up 10.3 percent on an operational basis. AbbVie raised its 2026 adjusted diluted EPS guidance to a range of $14.08 to $14.28. All figures are sourced from AbbVie's Q1 2026 financial results published April 29, 2026, via the AbbVie News Center.